Related Experiment Video
Updated: Oct 28, 2026
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Measuring up: the need for new assays for factor (F)XI/FXIa inhibitor therapies
David Gailani1, Melissa F Glasner2, Rasha Al-Lamee3
1Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Background:
As factor (F)XI/FXIa inhibitors advance through clinical development, a central challenge is determining how to assess their anticoagulant effects in routine practice.
Laboratory Assessment:
Assays such as the activated partial thromboplastin time and FXI activity tests demonstrate dose-dependent changes with these agents but are limited by reagent variability, poor standardization, and weak correlation with bleeding risk. No Food and Drug Administration-approved or standardized assay currently exists to reliably quantify FXI/FXIa inhibition or guide clinical decision making.
Clinical Implications:
Available clinical data suggest FXI/FXIa inhibitors provide robust antithrombotic efficacy with low bleeding risk, reducing the need for routine monitoring compared with traditional anticoagulants. However, patients often exhibit markedly prolonged activated partial thromboplastin time values that may be misinterpreted in acute settings, especially during surgery or episodes of bleeding. Conventional assays lack reliability for guiding care.
Future Directions:
Developing standardized monitoring strategies and institutional protocols will be critical to support safe integration of these agents, ensure consistency across care settings, and guide management in special clinical situations.
